Hemispherx registers $27.67 million of stock for at-the-market sales

Maxim assists in funding commercialization of Alferon and Ampligen

By Devika Patel

Knoxville, Tenn., Aug. 5 – Hemispherx Biopharma, Inc. registered $27,668,600 of common stock for its at-the-market offering with agent Maxim Group LLC, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission. The agreement was negotiated for $75 million, and the company has sold 105,908,814 shares under this deal.

Maxim will be paid a 3% commission.

Proceeds will be used for the commercialization of Alferon and Ampligen, research and development, along with general corporate purposes.

Philadelphia-based Hemispherx develops drugs to treat debilitating disorders, like viral diseases and immune-system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.